Kallyope rebranded as TriGemX Bio and shifted focus exclusively to migraine, after a Novo obesity-related deal prompted corporate restructuring. The company said it will support and advance its Phase 3 migraine program tied to a former Tanabe Pharma asset. The reorganization is designed to concentrate resources on the late-stage development work and align the company’s operational plan with its updated pipeline and investment priorities. For migraine development, TriGemX’s Phase 3 push reinforces how obesity and cardiometabolic strategies are reshaping biotech portfolios, with some assets being reallocated as platforms refocus on the highest-probability clinical catalysts.